FRACTYL HEALTH/GUTS

$7.56

1.7%
-
1D1W1MYTD1YMAX

About FRACTYL HEALTH

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Ticker

GUTS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Harith Rajagopalan

Employees

102

Headquarters

Burlington, United States

FRACTYL HEALTH Metrics

BasicAdvanced
$349M
Market cap
-
P/E ratio
-$1.73
EPS
-
Beta
-
Dividend rate
$349M
$14.50
$5.75
301K
9.379
9.373
34.088
34.088
-5.1%
2,356.01
4.142
4.142

What the Analysts think about FRACTYL HEALTH

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
191.01% upside
High $26.00
Low $18.00
$7.56
Current price
$22.00
Average price target

FRACTYL HEALTH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$3.3M
-82.72%
Profit margin
0%
NaN%

FRACTYL HEALTH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 43.33%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.17
-
Expected
-$0.30
-$0.46
Surprise
-43.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for FRACTYL HEALTH stock?

FRACTYL HEALTH (GUTS) has a market cap of $349M as of May 24, 2024.

What is the P/E ratio for FRACTYL HEALTH stock?

The price to earnings (P/E) ratio for FRACTYL HEALTH (GUTS) stock is 0 as of May 24, 2024.

Does FRACTYL HEALTH stock pay dividends?

No, FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders as of May 24, 2024.

When is the next FRACTYL HEALTH dividend payment date?

FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders.

What is the beta indicator for FRACTYL HEALTH?

FRACTYL HEALTH (GUTS) does not currently have a Beta indicator.

What is the FRACTYL HEALTH stock price target?

The target price for FRACTYL HEALTH (GUTS) stock is $22, which is 191.01% above the current price of $7.56. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell FRACTYL HEALTH stock

Buy or sell FRACTYL HEALTH stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing